Cel­gene's chemother­a­py Abrax­ane stum­bles in piv­otal pan­cre­at­ic can­cer study

Days af­ter Cel­gene’s Abrax­ane se­cured ap­proval in com­bi­na­tion with Roche’s check­point in­hibitor for front­line use in triple neg­a­tive breast can­cer, the US drug­mak­er re­port­ed that the chemother­a­py failed to im­prove pro­gres­sion-free sur­vival in a piv­otal study in­volv­ing pan­cre­at­ic can­cer pa­tients who had un­der­gone sur­gi­cal re­sec­tion.

Abrax­ane is al­ready ap­proved for use in var­i­ous can­cers: metasta­t­ic breast can­cer, metasta­t­ic non-small cell lung can­cer (NSCLC) as well as metasta­t­ic ade­no­car­ci­no­ma of the pan­creas as first-line treat­ment, in com­bi­na­tion with gem­c­itabine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER